Abstract Objective To understand the genetic load in the Chinese population for improvement in diagnosis, prevention and rehabilitation of deafness. Methods DNA samples, immortalized cell lines as well as detailed clinical and audiometric data were collected through a national genetic resources collecting network. Two conventional genetic approaches were used in the studies. Linkage analysis in X chromosome and autosomes with microsatellite markers were performed in large families for gene mapping and positional cloning of novel genes. Candidate gene approach was used for screening the mtDNA 12SrRNA, GJB2 and SLC26A4 mutations in population-based samples.
Introduction
The second national census in 2006（http://www.cdpf. org.cn）showed that there were a total of 82.96 million disabled people in China, of which 27.8 million（34%） had a hearing disability. This number continues to grow, with 30,000 new deaf cases every year. Currently, the on• ly effective intervention for congenital profound hearing loss or deaf patients is cochlear implantation. Currently in China, the minimal cost for cochlear implantation and following rehabilitation is 300,000 yuan（roughly $44, 118） . A total treatment cost for the 27.8 million people would be 8,000 billion yuan （$1,176 billions） . The annu• al incremental medical cost for the 30,000 new deaf ba• bies could impose an up to 9 billion yuan（$1.3 billion） bill on China economy. Rapidly accumulating evidence in the last decades demonstrates that genetic factors con• tribute substantially and broadly to communication disor• ders in various races and geographic regions in the world. Therefore, there is a great demand for genetic studies to elucidate the underlying mechanisms for he• reditary hearing loss, which can provide increased in• sights onto developing effective prevention and interven• tional measures.
Genetic factors contribute to 50% of deafness cases including syndromic（30%）and non-syndromic（70%） hearing impairment ［1, 2］ . Recent times have witnessed rapid progress in the field of genetic studies of hereditary hear• ing impairment, especially of non-syndromic hearing im• pairment. Transmission of non-syndromic hearing im• pairment can be autosomal recessive（77%） , autosomal dominant（22%） , X-linked（1%） , matrili-neal （mito• chondrial inheritance, about 1%） , or Y-lin-ked
［3-5］
. More than 146 chromosomal loci and at least 78 genes （http://webhost.ua.ac.be/hhh） have been identified so far. Recent advancements in hearing loss genetic studies have provided a better understanding of the genetic mu• tations that cause prelingual deafness
［6］
. There have been reports revealing that prelingual severe or profound hearing loss is mainly due to recessive inheritance, and the mutations in GJB2（DNFB1, OMIM: 121011) and SLC26A4（DFNB4, OMIM: 600791）genes are thought to be the major causes of autosomal recessive nonsyn• dromic deafness
［7］
. GJB2 gene mutation is currently rec• ognized to be respon-sible for both nonsyndromic auto• somal recessive and sporadic prelingual deafness
. Mutations in the SLC26A4 gene have been identified as a major cause for nonsyndromic hearing loss associated with enlarged vestibular aqueduct（EVA）and Pendred syndr-ome
. The 1555A>G mitochondrial mutation in the highly conserved coding region of the mitochondri• al 12S rRNA gene has been found to be the most preva• lent mitochondrial mutation associated with both amino• glycoside-induced and nonsyndromic sensorineural hearing loss（OMIM: 561000）in many ethnic origins 
Methods

Subject collection and audiological evaluation
Genetic resources are essential for finding novel loci/ genes and for characterizing genetic epidemiological pa• rameters of hereditary hearing loss. With the help from the Audiology Development Foundation of China （in provincial, municipal and county jurisdictions） , we ini• tialized a nation-wide campaign in 2000 for collecting genetic resources related to hearing loss and for con• structing a large-scale database to document Chinese patients including case-enriched families or sporadic subjects. Subjects in the studies were either identified through the national network covering most regions of China or from patients who directly visited our clinic. Control subjects were either randomly sampled normal hearing individuals or patients of different disease cate• gorizations than the phenotype under this study. Addi• tional efforts were devoted in collecting pedigree-based samples once a proband was identified, including pedi• gree extension by procuring the demographic and audio• metric data, and DNA samples for their relatives. Clinical evaluation was conducted according to the protocols approved by the PLA General Hospital IRB. All participants were extensively interviewed by experi• enced otoloaryngologists to identify personal or family evidence of hearing impairment, tinnitus, vestibular symptoms, use of aminoglycosides, and other clinical ab• normalities. These subjects were then given physical ex• aminations of the hair, skin, sclera, iris, mouth, maxilla, mandible, eyes, interocular distance, spine, and extremi• ties. Otolaryngological examinations focused on the auri• cle, external auditory meatus, and tympanic membrane. Audiometric evaluation included pure tone audiometry, tympanometry and acoustic reflexes, and auditory brain• stem responses. The audiometric data were categorized based on the recommendations by the European HEAR project, as described by Stephens
［14］
. Sensorineural hear• ing impairment was defined as an air/bone gap ⦤15 dB hearing loss averaged over 0.5, 1, and 2 kHz. The severi• ty of hearing impairment was applied to the better hear• ing ear, averaged over 0.5, 1, 2, and 4 kHz and catego• rized as following: mild: 20-40 dB HL; moderate: 41-70 dB HL; severe: 71-95 dB HL; and profound: > 95 dB HL. Frequency ranges were defined as following: low fre• quencies: ⦤ 0.5 kHz; mid frequencies: between 0.5 and 2 kHz（including 2 kHｚ） ; high frequencies: between 2 and 8 kHz (including 8 kHz） ; and extended high fre• quencies: > 8 kHz.
Molecular procedures for DNA isolation, genotyp• ing and sequencing
Genomic DNA from peripheral blood leukocytes was obtained by the phenol/chloroform method. All PCR am• plified products for the target fragments（microsatellites or gene fragments for genes GJB2, SLC26A4 and mtDNA 12S rRNA A1555G） were purified with the Millipore plate, and genotyped or sequenced with an ABI 3730 Se• quencer（Applied Biosystems） . Genotypes at > 400 mo• lecular markers, covering human genome every 10 cM each, were used for linkage analysis. Sequence data were analyzed by aligning with the reference sequences in NCBI （NC_000013 for GJB2, NT_007933 for SLC26A and AC_000021 for mtDNA 12S rRNA A1555G）using the DNAStar 5.0 and BioEdit software. Mutations or polymorphisms were identified per reference sequences.
GJB2 mutation screening The GJB2 gene has two ex• ons, and the coding region is in exon 2. With the use of the Primer 5.0 software package, the primer pair-for• ward primer（GJB2-F） : TGCTTACCCAGACTCGAGAA and reverse primer（GJB2-R） : CGACTGAGCCTTGA• CAGCTGA, were designed for the coding region of GJB2, and the PCR product was an 864bp fragment. In order to amplify the exon, touch-down PCR with the an• nealing temperatures of T1 = 68℃（10 cycles）and T2 = 63℃（25 cycles）was carried out in an ABI 9700 ther• mal cycler. . Hence, the following se• quential procedures were used to systematically detect mutations in the SLC26A4 gene. PCR amplifications of five exons （8, 19, 10, 17 and 15）were first performed. If a mutation was not detected in these five exons, the DNA sample was further screened for mutations in exons 3, 4, 5, 7, 11, 12 and 14, respectively. Exons 3, 5, 8 and 15 were amplified using the primer pairs described pre• viously ［16］ , which were designed using the online Primer 3.0 software. For exons 4, 7, 10, 11, 12, 14, 17 and 19, the primer pairs were designed based on those in Van Laer et al a 767 bp mtDNA fragment （nt1229~nt1995）was ampli• fied using the annealing temperature of T=62℃ for 30 cycles. Alw26I digestion analysis was also used for de• tecting mtDNA A1555G. A volume of 6.0 μl of the PCR product was mixed with 2.0 μl of buffer and 0.2 μl of Alw26I restriction enzyme（Tango, Shanghai, China） . ddH2O was added to the mixture till the volume reached 25.0 μl. The reaction mixture was incubated at 37℃ for 150 minutes. The electrophoresis on the 2% agarose gel was run to examine the digested product. If the digested product showed the specific band for mtDNA A1555G, the PCR product was verified by direct sequencing.
Data analysis
Linkage analysis First, simple familial aggregation and transmission analysis was performed to identify the most likely inheritance models for the investigated fami• lies, after non-genetic environmental causes were ex• cluded. Then, a genome-wide model-based linkage analysis was performed, and two point or multi-point logarithm of odds（LOD）scores between the disease lo• cus and markers were calculated by LINKAGE software Candidate gene approach Genetic epidemiological studies of several common hearing loss genes in the Chi• nese population were conducted using candidate gene approach to establish their influence on the Chinese at large. To obtain the population genetic parameters such as mutation rates and genotypic relative risks, an exten• sive screening of mutations in the candidate genes was conducted for different geographic regions or nationali• ties in this largest eastern country. In our studies, three common genes （mtDNA 12S rRNA, GJB2 and SLC26A4）were focused on. For sporadic patients or au• tosomal recessive pedigrees with profound or fluctuating hearing loss, or patients with a history of exposure to oto• toxic medications, we used the candidate approach to characterize the genetic epidemiological profiles in Chi• nese deaf patients. Also, the three genes were used as the targets in our newborns screening. 
rRNA, GJB2 and SLC26A4）for 5,914 newborns coming from eight provincial jurisdictions（Table 1） . These re• sources provide us rich materials for developing rigorous projects in both clinical and basic scientific research in the domain of hearing science, and consequently for de• fining better intervention measures delivered to hearing impaired patients in China.
Large-scale genetic studies for identifying the unique mutation spectrum and high-risk loci in Chinese population
There is a worldwide interest in studying the pathogen• · ·101 ic variants, especially in the three common hearing loss genes （mtDNA 12S rRNA, GJB2 and SLC26A4）that con• fer high cross-race risks to multiple ethnic backgrounds and populations. Nevertheless, increasing evidence from previous studies indicates that not only the mutation rates are distinct, but also the genetic loci/variants can be quite different among different races. In several stud• ies, we performed large-scale genetic studies of the three genes in order to develop reliable genetic testing for the Chinese population. In total, we have screened 2, 567（either familial or sporadic）patients for 12S rRNA 1555G and GJB2 or SLC26A4 mutations. These large-scale efforts identified Chinese specific mutation hotspots and defined the unique spectrum
［15］
. In the study of 801 patients collected in the northwest re• gions（mainly Gansu province） ［16］ , 26.2% were found to result from mutations in the three genes and the muta• tion rate was 8.4% for mtDNA A1555G, 9.0% for GJB2 and 8.8% for SLC26A4, respectively. About 12% of the patients were GJB2 or SLC26A4 mutation-wild heterozy• gotes. As a result, the cumulative 38% of the patients were associated with genetic variations in the three com• mon genes. This genetic epidemiological study also dem• onstrated that 26.2% of the prelingual deafness in north• ern China could be detected at young ages by genetic testing of the three common hearing loss genes, allowing early intervention to help them in language acquisition.
Among the 1,120 pedigrees collected, 147 were found to have hearing loss resulting from GJB2 homozygotes or compound heterozygotes. Hearing loss in the 230 EVA pedigrees was due to SLC26A4 homozygotes or compound heterozygotes. And in 100 families, hearing loss was caused by 12SrRNA A1555G mutation. Hearing loss was from 12SrRNA C1494T in 3 pedigrees. All the pedigrees had two or more affected members and 42.8% of the pedigrees were associated with mutations in the three genes, while the cause of deafness was unknown in the remaining 57.2% families .
In the study （CT）scan of the temporal bone and magnetic resonance imaging（MRI）were used to examine structures of the cochlea and endolymphatic sac. All 21 exons of the SLC26A4 gene were sequenced. Of the EVA patients, 70% were found having a significant A-B gap at low fre• quencies（500 and 250 Hz） , covering a span of 15-95 dB HL. In 75% of the patients, the short latency nega• tive response（ASNR） was evoked during the routine ABR testing. The latency of ASNRs was 3.26 ± 0.57 ms. In this study, SLC26A4 gene mutations were detect• ed in 97.9% of the EVA patients. Based on these find• ings, we developed a systematic diagnosis procedure in• tegrating audiometric tests, CT and MRI scans, and
.
Positional cloning based on Chinese pedigrees and searching for novel loci candidate gene muta• tions
As shown in Table 2 , the novel loci identified in our lab were nominated as DFNC1, DFNA55 and DFNA56 in the autosomal dominant inheritance pedigrees. Of the eight large pedigrees, the Z002 pedigree was mapped on• to the DFNA4 locus at 19q13.2-13.4, and the F013 ped• igree onto 9q31.3-34.3（nominated as DFNA56） . The novel locus DFNC1 at 12p11.23-13 for autosomal domi• nant conductive hearing loss with congenital ptosis was identified using a four-generation pedigree with nine pa• tients affected by this disorder. The Z029 pedigree was mapped onto 11q13.4-22.1, the 686 pedigree onto 9p13.2-13.3（nominated as DFNA55） , and the 727 pedigree onto 1p31-35, a region partially overlap• ping with DFNA47. The linkage for the remaining two pedigrees （1301 and 1318）was yet to be characterized.
Besides the autosomal dominant gene mappings, two novel mutations in POU3F4 causing congenital pro• found sensorineural hearing loss were found in two Chi• nese X-linked pedigrees
［22-24］
. The first pedigree repre• sented an exceptional case of more than eight males af• fected in one family with the phenotype of profound hear• ing loss leading to deaf-mutism caused by a POU3F4 de novo mutation that had not been reported before. Muta• tion screening of POU3F4 revealed a de novo missense Table 2 Linkage results for eight Chinese pedigrees following inheritance of autosomal dominance substitution（925T > C） in the well-known deaf gene. Very recently, another novel mutation in this gene was identified in another independent Chinese pedigree with CPSHI collected by our lab（unpublished data） .
In the positional cloning study, we mapped the first X-linked locus for auditory neuropathy, AUNX1, in a Chinese family
. We also mapped a Y-linked hear• ing impairment family on Y chromosome, nominated as DFNY1 locus. Recent studies showed that a novel mech• anism was responsible for the deafness phenotype . However, we have to recognize that follow-up positional cloning effort takes much lon• ger than identification of the susceptibility loci for hear• ing loss. The only exceptions are 1998 and 2001 when seven hearing loss genes were cloned in the respective year, giving an overoptimistic impression that the genet• ic basis for human auditory system could be fully decod• ed in the near future. However, with discoveries of a large number of new genetic loci for varied clinic audio• logical phenotypes, high heterogneities presented in sev• eral well-studied genes, multiple causal genes at a sin• gle Mendelian inheritance locus and modifier genes as well as evolutionary divergence of founder' s mutation, it is agreed by more people that fully deciphering the mo• lecular pathways of human hearing functionalities is still a very challenging task ［6, 31］ . In our otology clinic, when children with congenital profound hearing loss come, clinicians can reasonably believe that their symptoms may result from a GJB2 mu• tation at DFNB1 locus. This likelihood is 20%-50% . Likewise, when a patient is found sensitive to aminogly• coside ototoxicity and also has 12S rRNA 1555G, our cli• nicians will suggest averting the use of this type of drugs. When a patient is found having a POU3F4 muta• tion, the clinician will alert that the patient may be at risk of stapes gushers when an inner ear surgery is per• formed. Finally, early interventions may be given to an EVA patient with SLC26A4 mutation to prevent his pro• gressive hearing loss. In short, the recent advance in ge• netic studies of hearing loss is becoming an integrative component in designing most effective diagnosis for hearing loss and in delivering solid and convincing ad• vices to patients in otology clinic.
Nevertheless, before the genetic architecture underly• ing hereditary hearing phenotypes is fully understood, we have to face challenges in improving current clinic practice and research for hearing loss because of the par• tial or fragmented genetic knowledge accumulated so far. Large amount of work is to be completed, including deciphering the mutation-induced molecular mecha• nisms, biochemical or pathogenic pathways leading to varied phenotypes of hearing loss and phenotypic hetero• geneities. For examples, among the GJB2-induced pro• found hearing loss, the patients have different forms of mutations at the same（mutant homozygote）or different loci （compound heterozygotes） . In some cases, both the patient and his parent(s) have one mutant, but the parent 's hearing is normal. Among SLC26A4-induced EVA patients, more than 164 mutation types have been identi• fied
［15］
, but the resulted clinical phenotypes are largely indistinguishable from each other. For late onset hearing loss of dominant inheritance, it is unclear why patients with in-born pathogenic mutation demonstrate progres• sive hearing loss in their first or second decade. It re• mains a myth how environmental factors, post-transcrip• tion DNA methylation and various modifiers interplay with the underlying genetic network in the human audito• ry system. Some scientists estimate that 250-300 genes are related to the system, but only slight more than 70 genes are cloned. Pathogenic genetic factors for varieties of hearing loss phenotypes, such as noise-induced, age-related, idiopathic and neuropathy-associated hear• ing loss, are yet to be identified. To further understand the underlying functional mechanisms, mouse models may prove promising. However, translation of findings in these models to humans remains a challenging and is a largely unresolved issue. Although we are now in the stage of developing a matured molecular diagnosis for various types of hearing loss, congenital profound senso• rineural hearing loss in particular, the studies for post-diagnosis intervention are largely in infancy. Among others, regeneration of hair cells, gene therapy and development of personalized medication are likely future targets in the domain of otology clinic and science.
In otology clinics, early diagnosis and subsequently timely intervention are becoming the most effective strat• egy for improving hearing care in the largest population in the world. There are 800,000 deaf children under sev• en years of age in China. If we are able to fully imple• ment a national newborn genetic screening program, based on the knowledge that approximately 30% of deaf children are a result of gene mutations, 240,000 chil• dren are expected to receive timely intervention to avoid complete loss of their communication ability. In the meantime, 72 billions yuan of medical cost can be saved. In China, a yearly increment is the births of ap• proximately 30,000 deaf children. Based on these num• bers, genetic testing can help one third of these children and save 3,000 millions yuan for China. Therefore, we advocate an integration of genetic testing into the exist• ing newborn screening program. This conception will lead to identification of deaf mutation carriers in 3% of the populations. With planned birth in Chinese families, a substantial reduction in the genetic load and therefore the incidence rate of hearing suffers in the next genera• tion of this population is possible.
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